Market capitalization | JPY1.02t |
Enterprise Value | JPY888.42b |
PER (TTM) P/E ratio | 22.56 |
EV/FCF (TTM) EV/FCF | 16.79 |
EV/Sales (TTM) EV/Sales | 3.72 |
P/S ratio (TTM) P/S ratio | 4.28 |
P/B ratio (TTM) P/B ratio | 2.90 |
Dividend yield | 1.26% |
Last dividend (FY23) | JPY19.00 |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
14 Analysts have issued a M3 forecast:
14 Analysts have issued a M3 forecast:
Mar '24 | |
Current assets | 246,260 246,260 |
Fixed assets | 244,520 244,520 |
Total Assets | 490,780 490,780 |
Mar '24 | |
Equity | 366,701 366,701 |
Debt capital | 124,080 124,080 |
Total Capital | 490,781 490,781 |
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
M3, Inc. engages in the provision of medical related services through the Internet. It operates through the following segments: Medical Portal, Evidence Solutions, Overseas, Clinical Platform, and Others. The Medical Portal segment provides the medical-related marketing support and research services. The Evidence Solutions segment includes clinical research support business, medical clinical trials management, and management support business. The Overseas segment offers marketing support and research services for medical-related firms in the United States, the United Kingdom, and South Korea. The Clinical Platform segment engages in the development, sale and support of electronic medical records. The Others segment offers information services for medical institutions and prescription drug advertising business. The company was founded on September 29, 2000 and is headquartered in Tokyo, Japan.
Head office | Japan |
CEO | Itaru Tanimura |
Employees | 12,100 |
Founded | 2000 |
Website | corporate.m3.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.